RapidAI Company Research Report



Company Overview



Name, Mission of the Company


RapidAI
Mission: Technology designed by clinicians, for clinicians, to dramatically improve patients' lives.

When Was the Company Founded and By Whom


  • Founded: 2009

  • Founders:

  • Dr. Greg Albers

  • Dr. Roland Bammer

  • Matus Straka


Key People in the Company


  • CEO: Karim Karti

  • Regulatory and Quality: Jim Rosa

  • Innovation and Technology: Amit Phadnis

  • Chief Business Officer: David Stoffel

  • Engineering, Research, and Development: Matus Straka

  • SVP, Growth & Revenue: James Mercadante

  • VP, Strategic Growth, Sales: Juan Shedrick

  • International Sales: Alex Oh

  • Human Resources: Betsy Brookes


Where is the Company Headquartered


  • Headquarters: San Mateo, California, USA


Number of Employees


No information available

Revenue of the Company


No information available

What is the Company Known For


  • Specialization: AI-based clinical decision support tools for vascular and neurovascular conditions.

  • Impact: 2,200 hospitals trust RapidAI technology, with its solutions touching 90 million lives over 15 years of technological development.


Products



What Products Do They Offer


  • Stroke Solutions:

  • Rapid NCCT Stroke Solution, Rapid NCCT, Rapid LVO, Rapid ICH, Rapid CTP, Rapid Hyperdensity, Rapid MRI, Rapid ASPECTS, Rapid Hypodensity, Rapid Workflow for Stroke, Rapid CTA, Rapid for Angio.

  • Aneurysm Solutions:

  • RapidAI for Aneurysm

  • Pulmonary Embolism Solutions:

  • Rapid PE

  • Analytics:

  • RapidAI Insights

  • Clinical Trials Solutions:

  • Rapid for Trials


High-Level Description of the Product and Key Features


1. Rapid NCCT Stroke Solution:
  • Description: Non-contrast CT imaging for stroke assessment.

  • Features: Detection of intracranial hemorrhage (ICH) and large vessel occlusion (LVO).


2. Rapid LVO:
  • Description: AI-powered tool for large vessel occlusion detection.

  • Features: Automated analysis of CT angiography images with notification of suspected LVO.


3. Rapid ICH:
  • Description: Intracranial hemorrhage detection.

  • Features: AI to quickly assess NCCT scans for suspected hemorrhage.


4. Rapid CTP:
  • Description: CT perfusion imaging.

  • Features: Advanced imaging for assessing blood flow in the brain.


5. Rapid Hyperdensity:
  • Description: Hyperdensity volume calculation.

  • Features: Automated calculation of hyperdense volume in a NCCT scan.


6. Rapid MRI:
  • Description: MRI imaging for stroke assessment.

  • Features: Advanced analysis and mapping capabilities for MRI images.


7. Rapid ASPECTS:
  • Description: Automated scoring tool.

  • Features: Assessment of early signs of brain infarction in stroke patients.


8. Rapid Workflow for Stroke:
  • Description: Comprehensive solution for stroke workflow.

  • Features: Streamlined process from triage to treatment.


9. Rapid PE:
  • Description: Pulmonary embolism detection.

  • Features: AI-powered detection and notification for pulmonary embolism.


10. RapidAI Insights:
  • Description: Analytics platform.

  • Features: Reports and insights on scan and treatment data.


Recent Developments



Recent Developments in the Company


  • 2023: RapidAI achieves 10 million scans milestone, reflecting its significant impact in patient care.

  • 2022-2024: Multiple FDA clearances, including Rapid NCCT Stroke and AI modules for new conditions like pulmonary embolism and subdural hematomas.

  • International Presence: Expanded to over 100 countries with significant impact on stroke care globally.


New Products Launched


  • 2023: Rapid NCCT Stroke – first FDA-cleared non-contrast CT imaging product for acute stroke triage.

  • 2022-2024:

  • Rapid PE Triage & Notification

  • Rapid RV/LV for pulmonary embolism care

  • Rapid Hyperdensity for hemorrhages

  • Rapid SDH for subdural hematoma detection


New Features Added to Existing Products


  • RapidAI Enhancements: Continuous improvements in AI modules and imaging capabilities to detect various neurovascular conditions.

  • Platform Updates: Introduction of RapidAI Insights for deeper analytical capabilities and better clinical decision support.


Any New Partnerships


  • 2023: $75 million growth investment led by Vista Credit Partners.

  • 2021-2024:

  • Partnership with Penumbra to enhance pulmonary embolism solutions.

  • Collaboration with Texas County Memorial Hospital to improve stroke care in rural Missouri.


Closing Note


RapidAI continues to innovate within the AI medical imaging sector, extending its market reach while enhancing critical decision support for clinicians globally.